{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ajmera V"],"funding":["NCATS NIH HHS","NIDDK NIH HHS","NHLBI NIH HHS","NIAAA NIH HHS"],"pagination":["1098-1106"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11023802"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["79(5)"],"pubmed_abstract":["<h4>Background and aims</h4>Recently, the American Gastroenterological Association and the American Association for the Study of Liver Diseases developed clinical pathways to evaluate populations at high risk for NAFLD. We assessed the diagnostic performance of the new guidance in a well-phenotyped cohort of patients with Type 2 diabetes mellitus (T2DM).<h4>Approach and results</h4>This prospective study enrolled patients age ≥50 years with T2DM. Participants underwent a standardized clinical research visit with MRI and ultrasound-based assessment of liver fat and stiffness and Enhanced Liver Fibrosis (ELF) testing. Of 417 participants (36% men) with T2DM with FIB-4 and MRE data, the prevalence of NAFLD was 64% and 12% had advanced fibrosis (MRE≥3.63 kPa). Applying the American Gastroenter"],"journal":["Hepatology (Baltimore, Md.)"],"pubmed_title":["Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes."],"pmcid":["PMC11023802"],"funding_grant_id":["K23 DK119460","U01 AA029019","U01 DK130190","R01 DK121378","R01 DK124318","UL1 TR001442","P30 DK120515","R01 DK106419","U01 DK061734","P01 HL147835"],"pubmed_authors":["Manousou P","Bettencourt R","Ajmera V","Loomba R","Tesfai K","Richards L","Lopez S","Cervantes V","Madamba E","Sandoval E"],"additional_accession":[]},"is_claimable":false,"name":"Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes.","description":"<h4>Background and aims</h4>Recently, the American Gastroenterological Association and the American Association for the Study of Liver Diseases developed clinical pathways to evaluate populations at high risk for NAFLD. We assessed the diagnostic performance of the new guidance in a well-phenotyped cohort of patients with Type 2 diabetes mellitus (T2DM).<h4>Approach and results</h4>This prospective study enrolled patients age ≥50 years with T2DM. Participants underwent a standardized clinical research visit with MRI and ultrasound-based assessment of liver fat and stiffness and Enhanced Liver Fibrosis (ELF) testing. Of 417 participants (36% men) with T2DM with FIB-4 and MRE data, the prevalence of NAFLD was 64% and 12% had advanced fibrosis (MRE≥3.63 kPa). Applying the American Gastroenter","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 May","modification":"2025-07-12T03:04:13.913Z","creation":"2025-07-12T03:04:13.913Z"},"accession":"S-EPMC11023802","cross_references":{"pubmed":["37862551"],"doi":["10.1097/hep.0000000000000635","10.1097/HEP.0000000000000635"]}}